市場調查報告書
商品編碼
1361129
鳳梨蛋白酶市場 - 按形式(粉末、液體)、按酵素強度(低、中、高)、按應用(食品和飲料、營養產品、藥品、化妝品和個人護理)及預測,2023 - 2032 年Bromelain Market - By Form (Powdered, Liquid), By Enzyme Strength (Low, Medium, High), By Application (Food & Beverages, Nutraceuticals, Pharmaceuticals, Cosmetics & Personal Care) & Forecast, 2023 - 2032 |
2023 年至 2032 年間,全球鳳梨蛋白酶市場的年複合成長率將達到 7%。消費者對鳳梨蛋白酶相關健康益處的認知不斷提高將推動產業成長。其抗炎和消化特性使其成為廣受歡迎的膳食補充劑。此外,天然和植物療法的不斷成長趨勢也推動了鳳梨蛋白酶的流行。此外,它在食品和製藥行業的應用,例如肉類嫩化和抗癌研究,也有助於市場成長。隨著注重健康的消費者和各行業不斷認知到其價值,鳳梨蛋白酶的市場規模預計將進一步擴大。
該行業公司併購數量的增加支持了市場的成長。例如,2023年1月,印度Sun Pharmaceutical Industries公司成功收購了Phlogam(含Trypsin BP 48 mg、Bromelain 90 mg和Rutoside Tri Hydro 100 mg)和Disperzyme(含Trypsin BP 96 mg、Bromelain 180)三個品牌。和芸香苷三水合物200 毫克。這些商標是從 Aksigen Hospital Care 收購的,這是一家總部位於孟買的醫療保健公司,以其科學實力和二十多年的行業經驗而聞名。
整個鳳梨蛋白酶市場根據形式、應用和地區進行分類。
2023年至2032年,液體細分市場將經歷重大發展。液體鳳梨蛋白酶是尋求方便、快速起效的解決方案以實現各種健康益處的消費者的首選。這種形式很容易融入飲料和食品中,這對個人和食品行業都有吸引力。液體鳳梨蛋白酶的多功能性和易用性正在推動其在鳳梨蛋白酶市場前景中越來越受歡迎。
營養保健品領域從2023 年到2032 年將實現令人稱讚的年複合成長率。鳳梨蛋白酶源自鳳梨,因其消化和抗炎特性而聞名,使其成為膳食補充劑和營養保健品中的寶貴成分。消費者擴大尋求天然和植物性療法,刺激了該領域鳳梨蛋白酶的市場需求。其多功能應用和健康益處正在推動營養保健品市場的成長。
從 2023 年到 2032 年,歐洲鳳梨蛋白酶市場將呈現可觀的年複合成長率。這一趨勢是由人們越來越認知到鳳梨蛋白酶的健康益處(例如抗炎和消化特性)而推動的。此外,對天然和植物性療法的偏好與鳳梨蛋白酶的特性一致。它在膳食補充劑和食品工業中作為嫩肉劑的應用使其越來越受歡迎。隨著歐洲消費者優先考慮健康和保健,鳳梨蛋白酶市場不斷擴大。
Global Bromelain Market will witness 7% CAGR between 2023 and 2032. Increasing consumer awareness of the health benefits associated with Bromelain will drive industry growth. Its anti-inflammatory and digestive properties make it a sought-after dietary supplement. In addition, the growing trend toward natural and plant-based remedies has propelled Bromelain's popularity. Furthermore, its applications in the food and pharmaceutical industries, such as meat tenderization and anti-cancer research, contribute to market growth. As health-conscious consumers and various industries continue recognizing its value, the bromelain market size is expected to expand further.
The rising number of company mergers and acquisitions in the industry supports market growth. For instance, in January 2023, Indian company Sun Pharmaceutical Industries successfully acquired three brands, namely, Phlogam, which contains Trypsin BP 48 mg, Bromelain 90 mg, and Rutoside Trihydrate 100 mg, and Disperzyme, which contains Trypsin BP 96 mg, Bromelain 180 mg, and Rutoside Trihydrate 200 mg. These trademarks were acquired from Aksigen Hospital Care, a Mumbai-based healthcare company renowned for its scientific prowess and more than two decades of industry experience.
The overall Bromelain Market is classified based on form, application, and region.
The liquid segment will undergo significant development from 2023 to 2032. Liquid Bromelain is preferred by consumers seeking convenient and fast-acting solutions for various health benefits. This form is easy to incorporate into beverages and food products, making it attractive to both individuals and the food industry. The versatility and ease of use of liquid bromelain are driving its growing popularity in the bromelain market outlook.
The nutraceuticals segment will register a commendable CAGR from 2023 to 2032. Bromelain, derived from pineapples, is recognized for its digestive and anti-inflammatory properties, making it a valuable ingredient in dietary supplements and nutraceutical products. Consumers are increasingly seeking natural and plant-based remedies, fueling the bromelain market demand in this sector. Its versatile applications and health benefits are driving growth in the nutraceutical market.
Europe Bromelain market will showcase an appreciable CAGR from 2023 to 2032. This trend is driven by a growing awareness of its health benefits, such as anti-inflammatory and digestive properties. Additionally, the preference for natural and plant-based remedies aligns with Bromelain's profile. Its applications in dietary supplements and as a meat tenderizer in the food industry contribute to its increasing popularity. As consumers in Europe prioritize health and wellness, the Bromelain market continues to expand.